Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 2.
doi: 10.1002/oby.70003. Online ahead of print.

Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice

Samuel Frey  1   2 , Clément Louis-Gaubert  1   2 , Amélie Thouzeau  1 , Lola Cossé  1   2 , Victoria Lorant  1 , Xavier Prieur  1 , Laurent Flet  3 , Bertrand Cariou  1 , Claire Louis Blanchard  1   2 , Cédric Le May  1
Affiliations

Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice

Samuel Frey et al. Obesity (Silver Spring). .

Abstract

Objective: This proof-of-concept study evaluated the impact of adding semaglutide as an adjuvant therapy to sleeve gastrectomy (SG) on weight loss and metabolic outcomes in obese mice.

Methods: C57Bl6/J male received for 12 weeks high-fat diet and 20% fructose-enriched water, then they were randomized to undergo SG or a Sham surgery and were subsequently treated with either semaglutide or a vehicle for 8 weeks. Mice were weighed weekly, and food intake, plasma glucose levels, and adipose tissue weights were measured.

Results: Both SG and semaglutide alone significantly reduced body weight compared with Sham surgery (-22.9%, p = 0.049 and -28.2%, p = 0.003, respectively). SG and semaglutide combination resulted in the greatest reduction (-30.0%, p = 0.003). Food intake was only significantly decreased in the semaglutide group. Although SG has no significant effect, semaglutide alone and in association with SG significantly decreased the plasma glucose concentration. The combination also led to a significant reduction in plasma cholesterol levels (-37.5% ± 4.8% vs. 5.6% ± 6.8%, p = 0.023). Liver steatosis was reduced in all treated groups.

Conclusions: Adding semaglutide to SG potentiates weight loss and metabolic benefits of surgery in obese mice, but no more than with semaglutide alone. These findings support further investigation of combined surgical and pharmacological approaches in obesity treatment.

Keywords: bariatric surgery; diabetes; obesity; semaglutide; sleeve gastrectomy.

PubMed Disclaimer

References

    1. G. Mingrone, S. Panunzi, A. De Gaetano, et al., “Bariatric‐Metabolic Surgery Versus Conventional Medical Treatment in Obese Patients With Type 2 Diabetes: 5 Year Follow‐Up of an Open‐Label, Single‐Centre, Randomised Controlled Trial,” Lancet 386, no. 9997 (2015): 964–973, https://doi.org/10.1016/S0140‐6736(15)00075‐6.
    1. J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., “Once‐Weekly Semaglutide in Adults With Overweight or Obesity,” New England Journal of Medicine 384, no. 11 (2021): 989–1002, https://doi.org/10.1056/NEJMoa2032183.
    1. M. Shah and A. Vella, “Effects of GLP‐1 on Appetite and Weight,” Reviews in Endocrine & Metabolic Disorders 15, no. 3 (2014): 181–187, https://doi.org/10.1007/s11154‐014‐9289‐5.
    1. L. J. Aronne, D. B. Horn, C. W. le Roux, et al., “Tirzepatide as Compared With Semaglutide for the Treatment of Obesity,” New England Journal of Medicine 393 (2025): 26–36, https://doi.org/10.1056/NEJMoa2416394.
    1. M. Davies, L. Færch, O. K. Jeppesen, et al., “Semaglutide 2·4 mg Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double‐Blind, Double‐Dummy, Placebo‐Controlled, Phase 3 Trial,” Lancet 397, no. 10278 (2021): 971–984, https://doi.org/10.1016/S0140‐6736(21)00213‐0.

LinkOut - more resources